Lomitapide, Lomitapide Mesilate

Lomitapide is a microsomal triglyceride transfer protein inhibitor that inhibits the synthesis of chylomicrons and very low density lipoproteins. It is indicated in the treatment of homozygous familial hypercholesterolemia. Oral administration once daily. Daily supplements of vitamin E and fatty acids should be taken at the same time.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution, moderately high molecular weight and very high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

Its very low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.

It is teratogenic in animals and there is a high risk of hepatic alterations and severe diarrhea with dehydration with the use of this drug, so it is not advisable to use it during breastfeeding or pregnancy. ^{(Amryt 2022)}

Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

For considerations on the appropriateness of lipid-lowering therapy during lactation see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.

See below the information of this related product:

• Maternal Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia (Safe product and/or breastfeeding is the best option.)